JP2012514006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514006A5 JP2012514006A5 JP2011543717A JP2011543717A JP2012514006A5 JP 2012514006 A5 JP2012514006 A5 JP 2012514006A5 JP 2011543717 A JP2011543717 A JP 2011543717A JP 2011543717 A JP2011543717 A JP 2011543717A JP 2012514006 A5 JP2012514006 A5 JP 2012514006A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- disorder
- hydrogen
- carbons
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052757 nitrogen Inorganic materials 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 239000001257 hydrogen Substances 0.000 claims description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 208000028017 Psychotic disease Diseases 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 230000003542 behavioural effect Effects 0.000 claims description 6
- 150000002825 nitriles Chemical class 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 4
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 4
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000016285 Movement disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 2
- 208000031091 Amnestic disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 206010012218 Delirium Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000036626 Mental retardation Diseases 0.000 claims description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000027465 Psychotic Affective disease Diseases 0.000 claims description 2
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 claims description 2
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 230000001066 destructive effect Effects 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 208000009985 drug-induced dyskinesia Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 230000027682 synaptic transmission, glycinergic Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims 1
- 230000006870 function Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14103008P | 2008-12-29 | 2008-12-29 | |
| US61/141,030 | 2008-12-29 | ||
| PCT/US2009/069716 WO2010078348A1 (en) | 2008-12-29 | 2009-12-29 | 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012514006A JP2012514006A (ja) | 2012-06-21 |
| JP2012514006A5 true JP2012514006A5 (enExample) | 2013-01-31 |
Family
ID=42310195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543717A Pending JP2012514006A (ja) | 2008-12-29 | 2009-12-29 | ３．１．０二環式ＧｌｙＴ１阻害剤ならびにその作製および使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8497289B2 (enExample) |
| EP (1) | EP2381941A4 (enExample) |
| JP (1) | JP2012514006A (enExample) |
| KR (1) | KR20110117087A (enExample) |
| CN (1) | CN102271677A (enExample) |
| AU (1) | AU2009335120A1 (enExample) |
| BR (1) | BRPI0923878A2 (enExample) |
| CA (1) | CA2747602A1 (enExample) |
| IL (1) | IL213541A0 (enExample) |
| MX (1) | MX2011006845A (enExample) |
| RU (1) | RU2011124709A (enExample) |
| WO (1) | WO2010078348A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| KR20220102662A (ko) * | 2014-05-06 | 2022-07-20 | 노쓰웨스턴유니버시티 | Nmdar 조절 화합물의 조합물 |
| WO2016179351A1 (en) | 2015-05-05 | 2016-11-10 | Northwestern University | Treatment of levodopa-induced dyskinesias |
| PH12021552741A1 (en) * | 2019-05-01 | 2022-07-11 | Boehringer Ingelheim Int | Solid forms of a glyt1 inhibitor |
| BR112022026698A2 (pt) | 2020-08-13 | 2023-02-23 | Boehringer Ingelheim Int | Tratamento da deficiência cognitiva associada à esquizofrenia |
| CN117567449A (zh) | 2020-10-13 | 2024-02-20 | 勃林格殷格翰国际有限公司 | 再加工方法 |
| JP2025528779A (ja) | 2022-08-09 | 2025-09-02 | シーザン ハイスーク ファーマシューティカル カンパニー リミテッド | Ｐｄｅ４ｂ阻害剤及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981168A (en) * | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| CA2542279C (en) * | 2003-10-14 | 2011-08-09 | Pfizer Products Inc. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| JP5055493B2 (ja) * | 2004-12-21 | 2012-10-24 | メルク シャープ エンド ドーム リミテッド | Ｇｌｙｔ１阻害薬としてのピペリジンおよびアゼチジン誘導体 |
| WO2006117754A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists |
| GB0523998D0 (en) * | 2005-11-25 | 2006-01-04 | Merck Sharp & Dohme | Therapeutic agents |
| KR20090077051A (ko) * | 2006-09-29 | 2009-07-14 | 액테리온 파마슈티칼 리미티드 | 3-아자-비시클로[3.1.0]헥산 유도체 |
-
2009
- 2009-12-29 KR KR1020117016603A patent/KR20110117087A/ko not_active Withdrawn
- 2009-12-29 US US12/648,972 patent/US8497289B2/en not_active Expired - Fee Related
- 2009-12-29 WO PCT/US2009/069716 patent/WO2010078348A1/en not_active Ceased
- 2009-12-29 BR BRPI0923878-6A patent/BRPI0923878A2/pt not_active IP Right Cessation
- 2009-12-29 JP JP2011543717A patent/JP2012514006A/ja active Pending
- 2009-12-29 CA CA2747602A patent/CA2747602A1/en not_active Abandoned
- 2009-12-29 EP EP09837121A patent/EP2381941A4/en not_active Withdrawn
- 2009-12-29 MX MX2011006845A patent/MX2011006845A/es not_active Application Discontinuation
- 2009-12-29 RU RU2011124709/04A patent/RU2011124709A/ru not_active Application Discontinuation
- 2009-12-29 CN CN2009801530939A patent/CN102271677A/zh active Pending
- 2009-12-29 AU AU2009335120A patent/AU2009335120A1/en not_active Abandoned
-
2011
- 2011-06-14 IL IL213541A patent/IL213541A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012514006A5 (enExample) | ||
| JP2017535586A5 (enExample) | ||
| JP2010529135A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| JP2010538001A5 (enExample) | ||
| TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| BR112012014807A2 (pt) | "compostos adequados para o tratamento de sinucleopatias" | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| JPWO2015163447A1 (ja) | ４環性化合物の新規結晶 | |
| RU2011124709A (ru) | ДВУЯДЕРНЫЕ ИНГИБИТОРЫ GlyT1 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| AR110443A1 (es) | Inhibidores de histona metiltransferasas | |
| MY167396A (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| JP2007500168A5 (enExample) | ||
| EA200970760A1 (ru) | Быстро диссоциирующие антагонисты рецептора 2 дофамина | |
| EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
| MX2009011415A (es) | Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion. | |
| JP2013537240A5 (enExample) | ||
| MX2013001965A (es) | Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1 | |
| EA200970553A1 (ru) | Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2 | |
| Li et al. | Synthesis of chiral GABAA receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression | |
| KR20110095400A (ko) | 아자비사이클로－트리플루오로메틸 벤즈아미드 유도체의 신규한 다형태 | |
| BR112014016218A2 (pt) | produto de reação, composição de reação e método para manufaturar uma amina polifuncional | |
| MD20120049A2 (ro) | Procedeu de sinteza si forme cristaline ale hidroclorurii de 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamida si a bazei libere, compozitii farmaceutice care le contin pentru tratamentul tulburarilor cognitive si psiho-comportamentale |